Celgene's GED-0301 a new era in Crohn's? Hold your horses
This article was originally published in Scrip
Executive Summary
Publication in the New England Journal of Medicine of the full Phase II results of Celgene's potentially disruptive treatment for Crohn's disease, mongersen (GED-0301), have renewed the excitement surrounding the product, but some experts are reining in their expectations, saying more evidence using biological endpoints of disease activity is needed for the drug.